Treatment of Seminoma Stage IIA with Retroperitoneal Lymph Node Metastases (1–2 cm)
Seminoma stage IIA is defined by limited retroperitoneal lymph node involvement, with metastatic nodes measuring between 1 and 2 cm in diameter. This presentation is clinically distinct from higher-volume or distant metastatic disease and warrants a specific management pathway.
Clinical scenario: Stage IIA seminoma with retroperitoneal lymph node metastases 1–2 cm in diameter. At this extent of nodal disease, patients may be candidates for locoregional treatment rather than systemic chemotherapy alone — a distinction that shapes the entire therapeutic approach.
Current evidence-based guidance for this scenario supports either a course of radiation therapy to the regional lymph nodes or a cisplatin-based chemotherapy regimen. The choice between these approaches depends on individual patient factors, including specific contraindications. The complete protocol specifies the selection criteria, eligible regimens, and conditions under which each option applies.
References
DOI: 10.1016/j.annonc.2022.01.002
- Whereas patients with limited retroperitoneal lymph node metastases only, i.e. stage IIA, may be managed by RT, treatment of more advanced seminoma consists principally of ChT according to the IGCCCG classification for advanced/metastatic disease.
- Treatment consists of either ChT according to IGCCCG recommendations or RT to para-aortic and ipsilateral iliac lymph nodes (30 Gy in 2 Gy fractions for stage IIA), without randomised trials comparing the outcomes.
- Treat patients with seminoma stage IIA with either RT (30 Gy in 2 Gy fractions) or cisplatin-based ChT (three cycles of BEP or four cycles of EP) according to IGCCCG recommendations.
View source ↗